These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 26010610)

  • 21. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
    Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
    Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative Metabolomics Reveals Heart Failure With Midrange Ejection Fraction as a Distinct Phenotype of Heart Failure.
    Zhao H; Shui B; Zhao Q; Hu Z; Shu Q; Su M; Zhang Y; Ni Y
    Can J Cardiol; 2021 Feb; 37(2):300-309. PubMed ID: 32795449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
    Bishu K; Deswal A; Chen HH; LeWinter MM; Lewis GD; Semigran MJ; Borlaug BA; McNulty S; Hernandez AF; Braunwald E; Redfield MM
    Am Heart J; 2012 Nov; 164(5):763-770.e3. PubMed ID: 23137508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiopulmonary exercise testing reflects similar pathophysiology and disease severity in heart failure patients with reduced and preserved ejection fraction.
    Guazzi M; Labate V; Cahalin LP; Arena R
    Eur J Prev Cardiol; 2014 Jul; 21(7):847-54. PubMed ID: 23382540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
    Cheng RK; Cox M; Neely ML; Heidenreich PA; Bhatt DL; Eapen ZJ; Hernandez AF; Butler J; Yancy CW; Fonarow GC
    Am Heart J; 2014 Nov; 168(5):721-30. PubMed ID: 25440801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloperoxidase, carnitine, and derivatives of reactive oxidative metabolites in heart failure with preserved versus reduced ejection fraction: A meta-analysis.
    Wong CN; Gui XY; Rabkin SW
    Int J Cardiol; 2024 Mar; 399():131657. PubMed ID: 38101703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
    Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
    Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
    Hahn VS; Petucci C; Kim MS; Bedi KC; Wang H; Mishra S; Koleini N; Yoo EJ; Margulies KB; Arany Z; Kelly DP; Kass DA; Sharma K
    Circulation; 2023 Apr; 147(15):1147-1161. PubMed ID: 36856044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
    Brouwers FP; de Boer RA; van der Harst P; Voors AA; Gansevoort RT; Bakker SJ; Hillege HL; van Veldhuisen DJ; van Gilst WH
    Eur Heart J; 2013 May; 34(19):1424-31. PubMed ID: 23470495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparable prognostic impact of BNP levels among HFpEF, Borderline HFpEF and HFrEF: a report from the CHART-2 Study.
    Kasahara S; Sakata Y; Nochioka K; Yamauchi T; Onose T; Tsuji K; Abe R; Oikawa T; Sato M; Aoyanagi H; Miura M; Shiroto T; Takahashi J; Miyata S; Shimokawa H;
    Heart Vessels; 2018 Sep; 33(9):997-1007. PubMed ID: 29569034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolomic Profile in HFpEF vs HFrEF Patients.
    Hage C; Löfgren L; Michopoulos F; Nilsson R; Davidsson P; Kumar C; Ekström M; Eriksson MJ; Lyngå P; Persson B; Wallén H; Gan LM; Persson H; Linde C
    J Card Fail; 2020 Dec; 26(12):1050-1059. PubMed ID: 32750486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is mechanical dyssynchrony a therapeutic target in heart failure with preserved ejection fraction?
    Menet A; Greffe L; Ennezat PV; Delelis F; Guyomar Y; Castel AL; Guiot A; Graux P; Tribouilloy C; Marechaux S
    Am Heart J; 2014 Dec; 168(6):909-16.e1. PubMed ID: 25458655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy.
    Schwartzenberg S; Redfield MM; From AM; Sorajja P; Nishimura RA; Borlaug BA
    J Am Coll Cardiol; 2012 Jan; 59(5):442-51. PubMed ID: 22281246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma amino acid metabolomic pattern in heart failure patients with either preserved or reduced ejection fraction: The relation to established risk variables and prognosis.
    Saleem TH; Algowhary M; Kamel FEM; El-Mahdy RI
    Biomed Chromatogr; 2021 Jul; 35(7):e5012. PubMed ID: 33119901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
    Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
    Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker.
    Bekfani T; Bekhite M; Neugebauer S; Derlien S; Hamadanchi A; Nisser J; Hilse MS; Haase D; Kretzschmar T; Wu MF; Lichtenauer M; Kiehntopf M; von Haehling S; Schlattmann P; Lehmann G; Franz M; Möbius-Winkler S; Schulze C
    Cells; 2022 May; 11(10):. PubMed ID: 35626711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure.
    Yu X; Sun Y; Zhao Y; Zhang W; Yang Z; Gao Y; Cai H; Li Y; Wang Q; Bian B; Nie J
    Int Heart J; 2015 May; 56(3):314-8. PubMed ID: 25902879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
    Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
    Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.